Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELODROME phase IIIb study of ranibizumab Port Delivery System refill intervals in neovascular age-related macular degeneration
MOH_2021-09-10_010241Phase 3Recruiting
- Sponsor
- Roche
- Start
- Apr 2021
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranibizumab in exudative macular degeneration (2 arms), sponsored by Roche. Started Apr 2021; status: recruiting.
02
Drugs
ranibizumab
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on MOH_2021-09-10_010241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-09-10_010241.